PSNL News and Press, Personalis Inc. From 11/19/19

Personalis, Inc. (Nasdaq:PSNL), a leader in advanced genomics for cancer, today announced a collaboration with Merck KGaA, Darmstadt, Germany, a leading science and technology company, to investigate novel biomarkers of response and mechanisms of resistance to cancer therapies. Merck KGaA, Da...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will participate in the AACR Tumor Immunology and Immunotherapy conference at the Boston Marriott Copley Place in Boston, MA, November 17-20, including poster presentations on Novembe...

Personalis ( PSNL ) is a stock which I have watched with great interest since it went public earlier this year, yet in August I was forced to conclude that the potential growth champion has much to prove. That observation has proven to be correct with shares down to $10 at the moment of wr...

Personalis, Inc. (PSNL) Q3 2019 Earnings Conference Call November 13, 2019 05:00 PM ET Company Participants Caroline Corner - Westwicke John West - President & CEO Aaron Tachibana - CFO Clinton Musil - Chief Business Officer Conference Call Participants Yih-Ming Tu - ...

Gainers: PING   +13.3% . SNDL   +12.2% . PRSP   +8.3% . PSNL   +7.5% . TGP   +6.5% . More news on: Ping Identity Holding Corp., Sundial Growers Inc., Perspecta Inc., Stocks on the move, Read more ...

Personalis (NASDAQ: PSNL ): Q3 GAAP EPS of -$0.22 beats by $0.02 . More news on: Personalis, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today reported financial results for the third quarter ended September 30, 2019. Third Quarter 2019 Highlights Record revenues of $17.2 million in the third quarter of 2019, versus $11.7 million in the thir...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of Personalis’ Cancer Whole Genome Sequencing which further extends Personalis’ portfolio of comprehensive cancer genomics services designed to maximize biological insights from...

Now is a great time to have biotech stocks in your portfolio. While biotech investing can be scary, because the small-cap companies are often unprofitable research-and-development labs, this is also where a lot of the cutting-edge science is happening. Let's see how Mirati Therapeutics (NA...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will participate in the Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harbor, MD, November 7-10, including poster presentations on November 8 th and 9 th . ...